Actively Recruiting

Age: 18Years - 100Years
All Genders
NCT07282015

Real-world Secukinumab Outcomes in Canadian HS Patients

Led by Novartis Pharmaceuticals · Updated on 2026-05-13

142

Participants Needed

13

Research Sites

113 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.

CONDITIONS

Official Title

Real-world Secukinumab Outcomes in Canadian HS Patients

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed.
  • Adult patients at the time of informed consent signature.
  • Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.
  • Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (67 days) prior to Baseline visit.
  • Patients who can understand written and spoken Canadian English or French.
Not Eligible

You will not qualify if you...

  • Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.
  • Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM.
  • Patients who have had any prior exposure to secukinumab (i.e., >7 days prior to the baseline visit).

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

Novartis Investigative Site

Calgary, Alberta, Canada, T2J 7E1

Actively Recruiting

2

Novartis Investigative Site

Winnipeg, Manitoba, Canada, R3M 3Z4

Actively Recruiting

3

Novartis Investigative Site

Fredericton, New Brunswick, Canada, E3B 1G9

Actively Recruiting

4

Novartis Investigative Site

Cobourg, Ontario, Canada, K9A 4J9

Actively Recruiting

5

Novartis Investigative Site

Hamilton, Ontario, Canada, L8P4B4

Actively Recruiting

6

Novartis Investigative Site

London, Ontario, Canada, N6H 5L5

Actively Recruiting

7

Novartis Investigative Site

Markham, Ontario, Canada, L3P 1X3

Actively Recruiting

8

Novartis Investigative Site

Mississauga, Ontario, Canada, L4W 0C2

Actively Recruiting

9

Novartis Investigative Site

Richmond Hill, Ontario, Canada, L4C 9M7

Actively Recruiting

10

Novartis Investigative Site

Toronto, Ontario, Canada, M4E 1R7

Actively Recruiting

11

Novartis Investigative Site

Saint-Jérôme, Quebec, Canada, J7Z 7E2

Actively Recruiting

12

Novartis Investigative Site

Sherbrooke, Quebec, Canada, J1L 0H8

Actively Recruiting

13

Novartis Investigative Site

Saskatoon, Saskatchewan, Canada, S7N0N5

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here